<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cetuximab, a monoclonal antibody against the epidermal growth factor receptor, inconsistently improves response rates (RR), progression-free survival (PFS) and overall survival (OS) in the first-line treatment of advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with K-ras <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We performed a meta-analysis of four trials where K-ras WT Pts received a fluoropyrimidine (infusional vs. bolus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) vs. <z:chebi fb="0" ids="31348">capecitabine</z:chebi>) and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> or irinotecan with and without cetuximab (CRYSTAL, OPUS, COIN and NORDIC VII trials) and two trials, where K-ras WT and mutant patients received cetuximab and a fluoropyrimidine (<z:chebi fb="0" ids="31348">capecitabine</z:chebi> in a German AIO study and infusional 5-FU in the CECOG study) with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> versus irinotecan </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to determine whether the choice of fluoropyrimidine or of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> versus irinotecan affects the response to cetuximab </plain></SENT>
<SENT sid="3" pm="."><plain>Meta-analysis was performed in the context of a mixed effects model with a random effect for each study </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Only patients treated with infusional 5-FU-based chemotherapy derived benefit from cetuximab </plain></SENT>
<SENT sid="5" pm="."><plain>Relative to infusional 5-FU, patients treated with <z:chebi fb="0" ids="31348">capecitabine</z:chebi>/bolus 5-FU-based doublet chemotherapy had a 42 % (95 % CI 21-58 %; p &lt; 0.001) decrease in response probability and a 52 % (95 % CI 20-93 %; p &lt; 0.001) and 33 % (95 % CI 7-65 %; p = 0.012) increase, respectively, in risk of progression and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The choice of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> or irinotecan did not affect benefit from cetuximab </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: The lack of benefit for cetuximab with <z:chebi fb="0" ids="31348">capecitabine</z:chebi>/bolus 5-FU regimens is unexpected </plain></SENT>
<SENT sid="8" pm="."><plain>Cetuximab should only be used with infusional 5-FU regimens in the first-line treatment of K-ras WT <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Further study is urgently needed to elucidate the basis of this observation </plain></SENT>
</text></document>